Subject characteristics by response to a single decitabine-primed induction chemotherapy cycle
| Characteristic . | Response . | ||
|---|---|---|---|
| CR . | PR . | NR . | |
| Median age, y (range) | 57 (37-60) | 50 (23-59) | 52 (50-58) |
| Sex, M:F | 8:9 | 7:3 | 1:2 |
| FLT3-mutated, no. subjects (%) | 2 (12) | 2 (20) | 0 (0) |
| Antecedent hematologic disorder, no. subjects (%) | 3 (18) | 4 (40) | 1 (33) |
| Prior chemotherapy, no. subjects (%) | 2 (12) | 2 (20) | 0 (0) |
| WBC, ×109/L | |||
| Median (range) | 16 (2.2-133) | 33 (1.5-211) | 2.6 (2.4-30) |
| > 50, no. subjects (%) | 4 (24) | 4 (40) | 0 (0) |
| > 100, no. subjects (%) | 2 (12) | 3 (30) | 0 (0) |
| Platelet recovery peak, ×109/L | |||
| Median (range) | 670 (223-1386) | 282 (163-943) | 342 (66-359) |
| > 450, no. subjects (%) | 13 (76) | 4 (40) | 0 (0) |
| Cytogenetics, no. subjects (%) | |||
| Normal | 7 (41) | 3 (30) | 2 (67) |
| −7/del(7q) | 4 (24) | 1 (10) | 1 (33) |
| Complex | 2 (12) | 3 (30) | 0 (0) |
| abn(12p) | 2 (12) | 0 (0) | 0 (0) |
| abn(11q23) | 4 (24) | 0 (0) | 0 (0) |
| +8 | 0 (0) | 3 (30) | 0 (0) |
| t(6;9)(p23;q34) | 1 (6) | 0 (0) | 0 (0) |
| t(2;11)(q31;p15) | 0 (0) | 1 (10) | 0 (0) |
| ≥ 1 Adverse feature, no. subjects (%) | 15 (88) | 8 (80) | 2 (67) |
| Characteristic . | Response . | ||
|---|---|---|---|
| CR . | PR . | NR . | |
| Median age, y (range) | 57 (37-60) | 50 (23-59) | 52 (50-58) |
| Sex, M:F | 8:9 | 7:3 | 1:2 |
| FLT3-mutated, no. subjects (%) | 2 (12) | 2 (20) | 0 (0) |
| Antecedent hematologic disorder, no. subjects (%) | 3 (18) | 4 (40) | 1 (33) |
| Prior chemotherapy, no. subjects (%) | 2 (12) | 2 (20) | 0 (0) |
| WBC, ×109/L | |||
| Median (range) | 16 (2.2-133) | 33 (1.5-211) | 2.6 (2.4-30) |
| > 50, no. subjects (%) | 4 (24) | 4 (40) | 0 (0) |
| > 100, no. subjects (%) | 2 (12) | 3 (30) | 0 (0) |
| Platelet recovery peak, ×109/L | |||
| Median (range) | 670 (223-1386) | 282 (163-943) | 342 (66-359) |
| > 450, no. subjects (%) | 13 (76) | 4 (40) | 0 (0) |
| Cytogenetics, no. subjects (%) | |||
| Normal | 7 (41) | 3 (30) | 2 (67) |
| −7/del(7q) | 4 (24) | 1 (10) | 1 (33) |
| Complex | 2 (12) | 3 (30) | 0 (0) |
| abn(12p) | 2 (12) | 0 (0) | 0 (0) |
| abn(11q23) | 4 (24) | 0 (0) | 0 (0) |
| +8 | 0 (0) | 3 (30) | 0 (0) |
| t(6;9)(p23;q34) | 1 (6) | 0 (0) | 0 (0) |
| t(2;11)(q31;p15) | 0 (0) | 1 (10) | 0 (0) |
| ≥ 1 Adverse feature, no. subjects (%) | 15 (88) | 8 (80) | 2 (67) |
The majority of responders had at least 1 adverse prognostic feature.